Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenzhiling Oral Liquid for neurocognitive impairment (Alzheimer's disease) with TCM heart-spleen deficiency
ChiCTR2000040022Phase 4Recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) and cognitive disorder (CD) comparing Experimental group: Shenzhiling Oral Liquid with Control group: placebo (2 arms). Primary endpoint: Psychobehavioral symptoms. Started Jul 2017; status: recruiting.
02
Drugs
shenzhiling
03
Conditions
Alzheimer's disease (AD)cognitive disorder (CD)
Beyond the preview
Go deeper on ChiCTR2000040022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040022.